Quanterix Announces Closing of Public Offering Including Exercise in Full of Underwriters' Option to Purchase Additional Shares BILLERICA, Mass. (BUSINESS WIRE)

Quanterix Announces Closing of Public

Including Exercise in Full of Underwriters'

to Purchase Additional Shares

BILLERICA, Mass. (BUSINESS WIRE) - August 11, 2020- Quanterix

Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced

the closing of its previously announced underwritten public offering of 3,048,774 shares of its common stock at a public offering

price of $32.00 per share, including 397,666 shares sold pursuant to the full exercise of the underwriters' option to purchase

additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering

expenses, were approximately $97.6 million.

SVB Leerink and Cowen acted as joint bookrunning managers for

the offering. Canaccord Genuity acted as co-manager for the offering.

The public offering was made pursuant to a shelf registration

statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission ("SEC"),

as well as a related registration statement on Form S-3MEF filed with the SEC pursuant to Rule 462(b) under the Securities Act

of 1933, as amended. The final prospectus supplement and accompanying base prospectus relating to and describing the terms of the

offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov, and copies

of which can be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110,

by telephone at (800) 808-7525, ext. 6218 or by e-mail at syndicate@svbleerink.com, or Cowen and Company, LLC, c/o Broadridge Financial

Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by

email at PostSaleManualRequests@broadridge.com.

This press release shall not constitute an offer to sell, or

a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such

an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such

state or other jurisdiction.

Quanterix is a company that's digitizing biomarker analysis

with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential

to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from

health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced

treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently

being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and

infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"

"plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words

or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking

statements in this press release are based on Quanterix' expectations and assumptions as of the date of this press release.

Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results

to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix'

filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except

as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change

in expectations, even as new information becomes available.

Quanterix IR Contact:

Amol Chaubal, CFO, 617-301-9495

Quanterix PR Contact:

Staci Didner, 617-502-4300